Stephen Krahling was a published cancer researcher when vaccine maker Merck brought him on board as a virologist in 1999. That’s when he says he found himself embroiled in an all-hands-on-deck ...

Merck’s lupus drug enpatoran has failed to meet the primary endpoint in a subgroup of patients, but the drug's development is ...

Both Merck & Co. and Halozyme are holding their ground in a freshly unveiled patent dispute surrounding the New Jersey pharma ...

Merck's injected version of its blockbuster cancer drug Keytruda could face a potential patent challenge from biotech ...

Merck KGaA expects earnings and sales growth this year after reporting a rise in annual earnings on temporarily reduced ...

While the company is in discussions to acquire SpringWorks, it did not elaborate on these talks in its earnings call.

The company has asked the U.S. patent office to reconsider patents that could prevent it from selling an update to Keytruda.

Scientist Stephen Krahling worked on a project at Merck called “Protocol 7” and was uniquely positioned to blow the whistle on what he learned.

Shares in pharmaceuticals giant Merck (MRK) weakened today on fears that a patent battle could jeopardize its plans to sell a ...

Merck KGaA on Thursday forecast currency-adjusted operating earnings growth of up to 8%, helped by demand for semiconductor ...

What we want to do is remove about 0.35 acres of current site wetlands, in exchange for wetlands that are already in place, ...